ENDPOINTS NEWS42 分钟
Ex­clu­sive: Buck­ing gene-edit­ing down­turn, Tune rais­es $175M to bring epi­ge ...
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...
ENDPOINTS NEWS23 小时
Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war
NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.